Prostate Cancer Education
The prostate cancer treatment landscape has expanded with novel hormonal agents, PARP inhibitors, radiopharmaceuticals, and earlier use of combination therapy. Knowledge Med sessions help community providers navigate treatment intensification and sequencing through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing prostate cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting among ARSI combinations in metastatic hormone-sensitive disease
- Identifying patients for PARP inhibitor therapy based on HRR status
- Integrating PSMA-targeted radioligand therapy in mCRPC
- Managing sequencing of multiple life-prolonging therapies
What Sessions Cover
Knowledge Med mCRPC sessions use interactive case simulations to address these topics and more.
- Treatment intensification in metastatic hormone-sensitive prostate cancer
- PARP inhibitors in HRR-deficient mCRPC: patient selection and monitoring
- PSMA-targeted therapy: lutetium-177 and emerging agents
- Sequencing ARSIs, taxanes, and novel agents in mCRPC
Interactive mCRPC Sessions
Case Simulations
Work through realistic prostate cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key mCRPC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a mCRPC Session
Third-party, non-promotional prostate cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session